Abstracts tagged "canakinumab and familial Mediterranean fever"

Abstract Number: 2863 • 2018 ACR/ARHP Annual Meeting
Long-Term Efficacy and Safety of Canakinumab in Patients with Colchicine-Resistant FMF (crFMF), Hids/Mkd and TRAPS: Results from the Pivotal Phase 3 Cluster Trial
Fabrizio De Benedetti¹, Joost Frenkel², Anna Simon³, Jordi Anton⁴, Helen J. Lachmann⁵, Marco Gattorno⁶, Seza Ozen⁷, Isabelle Koné-Paut⁸, Eldad Ben-Chetrit⁹, Magdalena Wozniak¹⁰, Xiaoling Wei¹¹ and Eleni Vritzali¹², ¹IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, ²University Medical Center,Utrecht, Utrecht, Netherlands, ³General Internal Medicine, Radboud University, Nijmegen Medical Centre, Nijmegen, Netherlands, ⁴Unitat de Reumatologia Pediàtrica, Hospital Sant Joan de Déu, Barcelona, Spain, ⁵UCL Division of Medicine, UK National Amyloidosis Centre, London, United Kingdom, ⁶Pediatric Division, G Gaslini Institute, Genoa, Italy, ⁷Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁸APHP, CHU de Bicêtre, University of Paris SUD, Paris, France, ⁹Rheumatology Unit, Hadassah—Hebrew University Medical Center, Jerusalem, Israel, ¹⁰Novartis Ireland Ltd, Dublin, Ireland, ¹¹China Novartis Institutes for Biomedical Research Co., Ltd, Beijing, China, ¹²Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Canakinumab (CAN), a selective, human anti-interleukin (IL)-1β has demonstrated efficacy and safety in patients (pts) with colchicine-resistant familial Mediterranean fever (crFMF), hyper-IgD syndrome (HIDS)/mevalonate…
Abstract Number: 2975 • 2018 ACR/ARHP Annual Meeting
Anti-Il-1 Therapies in Patients with Familial Mediterranean Fever Related AA-Amyloidosis
Bilgesu Ergezen¹, Serdal Ugurlu², Oguzhan Selvi³, Bugra Han Egeli⁴ and Huri Ozdogan³, ¹Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ²Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ³Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ⁴Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey
Background/Purpose: The most devastating complication of Familial Mediterranean Fever is secondary AA amyloidosis and is still a problem in many cases. Efforts have been paid…
Abstract Number: 1894 • 2017 ACR/ARHP Annual Meeting
Genetic Phenotypes Impacting Efficacy and Safety of Canakinumab in Patients with Colchicine-Resistant FMF, TRAPS and Hids/Mkd: Results from Cluster Study
Fabrizio De Benedetti¹, Paivi Miettunen², Tilmann Kallinich³, Gerd Horneff⁴, Riva Brik⁵, Alberto Tomassini⁶, Takahiro Yasumi⁷, Sinisa Savic⁸, Ivan Foeldvari⁹, Liora Harel¹⁰, Romina Gallizzi¹¹, Antonio Speziale¹², Guido Junge¹² and Marco Gattorno¹³, ¹Division of Rheumatology, IRCCS Bambino Gesù Children's Hospital, Rome, Rome, Italy, ²Alberta Children's Hospital Research Institute/University of Calgary, Calgary, AB, Canada, ³Charité, Humbolt University Medicine Berlin, Berlin, Germany, ⁴Asklepios Kliniken GmbH, Hamburg, Germany, ⁵Pediatrics, Rambam Medical Center, Haifa, Israel, ⁶Institute for Maternal and Child Health- IRCCS “Burlo Garofolo”, Trieste, Italy, ⁷Department of Pediatrics, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁸University of Leeds, Leeds, United Kingdom, ⁹Hamburger Zentrum für Kinder-und Jugend Rheumatologie, Hamburg, Germany, ¹⁰Schneider Children's Medical Center of Israel, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel, ¹¹Department of Pediatrics, University of Messina, Messina, Italy, ¹²Novartis Pharma AG, Basel, Switzerland, ¹³Pediatric Rheumatology, G. Gaslini Institute, Genoa, Italy
Background/Purpose: Familial Mediterranean fever (FMF), Hyper IgD Syndrome (HIDS)/mevalonate kinase deficiency (MKD) and TNF-receptor associated periodic syndrome (TRAPS) are monogenic auto-inflammatory diseases caused by mutations…
Abstract Number: 14 • 2017 Pediatric Rheumatology Symposium
Efficacy and Safety of Canakinumab in Patients with Periodic Fever Syndromes (Colchicine-Resistant FMF, HIDS/MKD and TRAPS): Results from a Phase 3, Pivotal, Umbrella Trial
Fabrizio De Benedetti¹, Jordi Anton², Eldad Ben-Chetrit³, Inmaculada Calvo⁴, Joost Frenkel⁵, Marco Gattorno⁶, Hal M. Hoffman⁷, Ozgur Kasapcopur⁸, Isabelle Koné-Paut⁹, Helen Lachmann¹⁰, Michel Moutschen¹¹, Seza Ozen¹², Pierre Quartier¹³, Anna Simon¹⁴, Andrew Zeft¹⁵, Karine Lheritier¹⁶, Antonio Speziale¹⁶ and Guido Junge¹⁶, ¹IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ²Unitat de Reumatologia Pediàtrica, Hospital Sant Joan de Déu, Barcelona, Spain, ³Rheumatology Unit, Hadassah—Hebrew University Medical Center, Jerusalem, Israel, ⁴Hospital Universitario y Polytecnico La Fe, Valencia, Spain, ⁵University Medical Center,Utrecht, Utrecht, Netherlands, ⁶Pediatric Rheumatology, G. Gaslini Institute, Genoa, Italy, ⁷Division of Rheumatology, Allergy, and Immunology, University of California at San Deigo, La Jolla, CA, ⁸Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University, Istanbul, Turkey, ⁹Hopital Kremlin Bicetre, University of Paris SUD, Paris, France, ¹⁰UK National Amyloidosis Centre, University College London Medical School, London, United Kingdom, ¹¹CHU de Liège/ University of Liège, Liège, Belgium, ¹²Department of Pediatrics, Hacettepe University, Ankara, Turkey, ¹³Necker-Enfants Malades Hospital, Paris, France, ¹⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ¹⁵Pediatrics Rheumatology, Cleveland Clinic, Cleveland, OH, ¹⁶Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Open-label studies have suggested the efficacy of canakinumab (CAN), a fully human, highly specific anti-IL-1β neutralizing monoclonal antibody, in colchicine-resistant-FMF (crFMF), hyper-immunoglobulin (Ig) D…
Abstract Number: 9L • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Canakinumab in Patients with Colchicine-Resistant Familial Mediterranean Fever, Hyper-Immunoglobulin D Syndrome/Mevalonate Kinase Deficiency and TNF Receptor-Associated Periodic Syndrome: 40 Week Results from the Pivotal Phase 3 Umbrella Cluster Trial
Fabrizio De Benedetti¹, Joost Frenkel², Inmaculada Calvo³, Marco Gattorno⁴, Michel Moutschen⁵, Pierre Quartier⁶, Ozgur Kasapcopur⁷, Seza Ozen⁸, Jordi Anton⁹, Isabelle Koné-Paut¹⁰, Helen Lachmann¹¹, Hal M. Hoffman¹², Eldad Ben-Chetrit¹³, Anna Shcherbina¹⁴, Michaël Hofer¹⁵, Philip J Hashkes¹⁶, Andrew Zeft¹⁷, Karine Lheritier¹⁸, Yankun Gong¹⁹, Antonio Speziale¹⁸ and Guido Junge¹⁸, ¹Division of Rheumatology, Ospedale Pediatrico Bambino Gesù IRCCS, Rome, Italy, ²University Medical Center Utrecht, Utrecht, Netherlands, ³Pediatric Rheumatology, Hospital Universitario i Politecnic La Fe, Valencia, Spain, ⁴Pediatric Rheumatology, G. Gaslini Institute, Genoa, Italy, ⁵C.H.U. Sart-Tilman, Liege, Belgium, ⁶Necker-Enfants Malades Hospital, Paris, France, ⁷Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University, Istanbul, Turkey, ⁸Department of Pediatrics, Division of Rheumatology, Hacettepe University Children's Hospital, Ankara, Turkey, ⁹Hospital Sant Joan de Déu, Barcelona, Spain, ¹⁰Department of Paediatric Rheumatology, Hôpital Kremlin Bicetre, University of Paris SUD, Paris, France, ¹¹UK National Amyloidosis Centre, University College London Medical School, London, United Kingdom, ¹²University of California, San Diego, La Jolla, CA, ¹³Rheumatology Unit, Hadassah—Hebrew University Medical Center, Jerusalem, Israel, ¹⁴Immunology, Federal Research and Clinical Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation, ¹⁵Unité romande d’immuno-rhumatologie pédiatrique, CHUV, University of Lausanne, Lausanne, Switzerland, ¹⁶Pediatrics Rheumatology; Shaare-Zedek Medical Center, Jerusalem, Israel, ¹⁷Pediatrics Rheumatology, Cleveland Clinic, Cleveland, OH, ¹⁸Novartis Pharma AG, Basel, Switzerland, ¹⁹Beijing Novartis Pharma Co. Ltd., Beijing, China

Background/Purpose: Evidence points to the role of abnormal IL-1β production in familial Mediterranean fever (FMF), hyper-immunoglobulin D syndrome/mevalonate kinase deficiency (HIDS/MKD) and TNF receptor-associated periodic…
Abstract Number: 247 • 2016 ACR/ARHP Annual Meeting
ANTI-Interleukin 1 Therapy in FMF Amyloidosis: A Single Center Experience
Serdal Ugurlu, Bilgesu Ergezen and Huri Ozdogan, Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey
Background/Purpose: Recently there is increasing number of reports pointing out the efficacy of anti-interleukin 1(anti-IL1)therapy to control AA amyloidosis secondary to autoinflammatory diseases. Here we…
Abstract Number: 942 • 2016 ACR/ARHP Annual Meeting
A Nationwide Experience with the Off Label Use of Interleukin 1 Targeting Treatment in Familial Mediterranean Fever Patients
Servet Akar¹, Pınar Cetin², Umut Kalyoncu³, Omer Karadag⁴, Ismail Sari⁵, Muhammed Cinar⁶, Sedat Yılmaz⁷, Ahmet Mesut Onat⁸, Bunyamin Kisacik⁹, Abdulsamet Erden³, Ayşe Balkarli¹⁰, Orhan Kucuksahin¹¹, Sibel Yilmaz Oner¹², Soner Senel¹³, Abdurrahman Tufan¹³, Haner Direskeneli¹², Mustafa Ferhat Oksuz¹⁴, Yavuz Pehlivan¹⁴, Ozun Bayndır¹⁵, Gokhan Keser¹⁶, Kenan Aksu¹⁷, Ahmet Omma¹⁸, Timucin Kasifoglu¹⁹, Ali Ugur Unal²⁰, Fatih Yildiz²¹, Mehmet Ali Balci²², Sule Yavuz¹³, Sukran Erten²³, Metin Ozgen²⁴, Mehmet Sayarlioglu²⁵, Atalay Dogru²⁶, Gozde Yildirim Cetin²⁷, Fatma Alibaz-Oner²⁰, Mehmet Engin Tezcan²⁸, Omer Nuri Pamuk²⁹ and Fatos Onen³⁰, ¹Department of Internal Medicine, Division of Rheumatology, Izmir Katip Celebi University School of Medicine, Izmir, Turkey, ²Dokuz Eylul University, izmir, Turkey, ³Hacettepe University, Ankara, Turkey, ⁴Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁵Rheumatology, Toronto Western Hospital, University of Toronto, Spondylitis Clinic, Toronto, ON, Canada, ⁶GATA, Ankara, Turkey, ⁷Division of Rheumatology, Gülhane Military Medical Academy, School of Medicine, Ankara, Turkey, ⁸Gaziantep University School of Medicine, Ankara, Turkey, ⁹Rheumatology, Gaziantep University School of Medicine, Gaziantep, Turkey, ¹⁰Antalya EAH, Antalya, Turkey, ¹¹Internal Medicine-Rheumatology, Yildirim Beyazit University Faculty of Medicine, Ankara, Turkey, ¹²Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ¹³PsART study group, Ankara, Turkey, ¹⁴Rheumatology, Uludag University Medcal Faculty, Bursa, Turkey, ¹⁵İnternal Medicine Division of Rheumatology, Ege University Medical Faculty, Izmir, Turkey, ¹⁶Rheumatology, Ege University Medical Faculty, Izmir, Turkey, ¹⁷Ege University, İzmir, Turkey, ¹⁸Department of Internal Medicine, Rheumatology Division, Ankara Numune Hospital, Ankara, Turkey, ¹⁹İnternal Medicine Division of Rheumatology, Osmangazi University, Faculty of Medicine, Eskisehir, Turkey, ²⁰Marmara University, School of Medicine, Rheumatology, Istanbul, Turkey, ²¹Rheumatology, Van EAH, Adana, Turkey, ²²Rheumatology, Trakya University Medical Faculty, Edirne, Turkey, ²³Rheumatology, Yildirim Beyazit University Faculty Of Medicine, Ankara, Turkey, ²⁴Department of Internal Medicine Division of Rheumatology, Ondokuz Mayıs University, Faculty of Medicine, Samsun, Turkey, ²⁵Rheumatology, Ondokuz Mayis University Faculty of Medicine, Samsun, Turkey, ²⁶Suleyman Demirel University, Isparta, Turkey, ²⁷Deparment of Rheumatology, Sutcu Imam University, School of Medicine, Department of Internal Medicine, Division of Rheumatology, Kahramanmaras, Turkey, ²⁸Internal Medicine-Rheumatology, Gazi University Medical School, Ankara, Turkey, ²⁹Rheumatology, Department of Rheumatology, Trakya University Medical Faculty, Edirne, Turkey, Edirne, Turkey, ³⁰Rheumatology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey
Background/Purpose: Familial Mediterranean fever (FMF) is the most common autoinflammatory disease and colchicine is the mainstay of treatment. Around 30-45% of FMF patients were reported…
Abstract Number: 1232 • 2014 ACR/ARHP Annual Meeting
Canakinumab Therapy in Patients with Familial Mediterranean Fever
Serdal Ugurlu, Emire Seyahi, Gulen Hatemi, Aysa Hacioglu, Fatma Nihan Akkoc and Huri Ozdogan, Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey
Background/Purpose: According to a recent pilot study Canakinumab reduced the frequency of attacks in 9 patients with Familial Mediterranean Fever (FMF) resistant to colchicine with no…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].